XenoPort, Inc. (XNPT) Reports Active Ingredient In Horizant Guidelines For Treatment Of Restless Legs Syndrome

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered and developed drug candidates for the potential treatment of neurological disorders. The company is currently commercializing its first FDA-approved product, Horizant.

The company announced today the inclusion of gabapentin enacarbil, the active ingredient in Horizant® (gabapentin enacarbil) Extended-Release Tablets, as a first-line therapy in new treatment guidelines created by the Task Force of the International Restless Legs Syndrome Study Group (IRLSSG). This disease is a neurological condition that causes those afflicted to have an irresistible urge to move the legs. The urge is usually accompanied by unpleasant sensations of burning, creeping, tugging, or tingling inside the legs.

Horizant is the only non-dopamine agent and the only alpha-2-delta ligand currently approved by the FDA for the treatment of moderate-to-severe primary restless legs syndrome in adults. The newly-released guidelines indicate that alpha-2-delta ligands be considered for initial treatment in patients with severe sleep disturbance, insomnia or anxiety, RLS/WED-related pain, or a history of an impulse control disorder or anxiety. The guidelines also recommend a long-acting agent for patients with clinically significant daytime symptoms.

The release of these guidelines is an important breakthrough for Xenoport. There is growing recognition that dopamine agonists are not a sufficient answer for long-term treatment of patients with the disease. Most importantly, Horizant product is being recognized as an key treatment option for patients with RLS/WED.

For further information about XenoPort Inc., its Horizant product, and its whole portfolio of drug candidates, please visit www.xenoport.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html